WHO Raises Concern Over Acute Lack of Obesity Injections

Less than one in 10 individuals eligible to benefit from weight-loss injections such as Wegovy can access them, warns the global health agency as it issues its inaugural recommendations on the drugs.

Considering over a billion people worldwide now obese, it is urging increased and just availability to GLP-1 medication.

Based on forecasts, over two billion will be living with obesity by 2030 unless action is taken.

"Our new guidance affirms that excess weight is a long-term condition that can be treated with comprehensive and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and logistical bottlenecks are significant obstacles to broad availability to the jabs that can assist patients in reducing significant weight, notes the body.

GLP-1 Therapy Scarcity

Despite the current most favorable case, the manufacturing of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, according to the health organization.

The guideline urges governments and firms to increase access, by measures including voluntary licensing.

Exclusive production rights on a key compound – the core ingredient of a leading brand – is set to lapse in several nations in 2026.

The Way Obesity Jabs Operate

The injections imitate a natural hormone to delay gastric emptying, curb appetite and boost the sense of being full so users reduce food intake.

Individuals typically start to lose weight after several weeks of commencing the regular doses.

Evidence indicates users may put most of the weight back on within a year of stopping the medication, when their normal food cravings return.

Being carrying excess weight raises your risk for developing diseases, including diabetes, heart disease, brain attack, and certain malignancies.

Excess weight affects people in all nations and was associated with millions of deaths worldwide in 2024, as per the health agency.